Cytosorbents Corporation (NASDAQ:CTSO) issued its quarterly earnings results on Monday. The medical research company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02, Bloomberg Earnings reports. Cytosorbents Corporation had a negative return on equity of 1,426.21% and a negative net margin of 108.69%.

Shares of Cytosorbents Corporation (NASDAQ CTSO) traded up 3.26% on Monday, hitting $4.75. The stock had a trading volume of 163,008 shares. The company’s market cap is $133.51 million. The firm has a 50 day moving average price of $4.53 and a 200-day moving average price of $4.90. Cytosorbents Corporation has a 52 week low of $3.30 and a 52 week high of $6.90.

A number of research analysts have recently commented on the company. Aegis reissued a “buy” rating and set a $9.00 price target on shares of Cytosorbents Corporation in a report on Tuesday, July 25th. B. Riley reissued a “buy” rating and set a $11.25 price target on shares of Cytosorbents Corporation in a report on Monday. Cowen and Company assumed coverage on Cytosorbents Corporation in a report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Maxim Group reissued a “buy” rating and set a $10.00 price target on shares of Cytosorbents Corporation in a report on Tuesday, April 25th. Six investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $12.38.

ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at

In other Cytosorbents Corporation news, insider Phillip P. Chan acquired 6,300 shares of Cytosorbents Corporation stock in a transaction on Monday, June 5th. The shares were bought at an average price of $4.00 per share, with a total value of $25,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders acquired 17,500 shares of company stock worth $70,620. Insiders own 5.60% of the company’s stock.

Cytosorbents Corporation Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Earnings History for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with's FREE daily email newsletter.